| P50 | author | Eileen M. O'Reilly | Q57517885 |
| | Nadim El Majzoub | Q84101713 |
| | Ghazi Zaatari | Q114398771 |
| P2093 | author name string | Manish Shah | |
| | Ali Shamseddine | |
| | Deborah Mukherji | |
| | Ghassan K Abou-Alfa | |
| | Mohamed Khalife | |
| | Walid Faraj | |
| P2860 | cites work | Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages | Q21092323 |
| | Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial | Q29547565 |
| | FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer | Q29547638 |
| | Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 |
| | Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer | Q33326148 |
| | Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes | Q33987127 |
| | Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study | Q34564463 |
| | Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer | Q34596369 |
| | Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704 | Q34600819 |
| | Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial | Q34602771 |
| | Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer | Q34613161 |
| | Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study | Q36222863 |
| | Intraductal papillary mucinous neoplasms of the pancreas: clinical and pathological features and diagnostic approach | Q37243655 |
| | Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup meta-analyses of overall survival | Q37690481 |
| | Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer | Q45148156 |
| | Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head | Q46473461 |
| | Clear cell endocrine pancreatic tumor mimicking renal cell carcinoma: a distinctive neoplasm of von Hippel-Lindau disease. | Q51066741 |
| | Clear cell carcinoma of the pancreas: histopathologic features and a unique biomarker: hepatocyte nuclear factor-1beta. | Q51699392 |
| | The clear cell variant of solid pseudopapillary tumor of the pancreas: a previously unrecognized pancreatic neoplasm. | Q51784586 |
| | Clear cell "sugar" tumor of the pancreas. A novel member of the family of lesions characterized by the presence of perivascular epithelioid cells | Q71126296 |
| | Invasive carcinoma derived from the nonintestinal type intraductal papillary mucinous neoplasm of the pancreas has a poorer prognosis than that derived from the intestinal type | Q82444407 |
| P433 | issue | 1 | |
| P304 | page(s) | 29-31 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | Gastrointestinal cancer research : GCR | Q27722152 |
| P1476 | title | A 71-year-old man with a large cystic pancreatic mass | |
| P478 | volume | 5 | |